Supplementary Information

Structural Basis for Cannabinoid-induced Potentiation of alpha1-Glycine Receptors in Lipid

Nanodiscs

Kumar et al

a



b

Supplementary Figure 1. (a) A continuous TEVC recording of WT GlyR currents activated by 0 .1 mM glycine in the absence and presence of 3.2 μ M THC. Membrane potential was held at -60 mV. (b) A representative trace from WT GlyR current recording with 1 mM glycine in the absence and presence of 3.2 μ M THC. (c) A representative trace from WT GlyR current recording with 0.1 mM glycine in the absence and presence of 32 μ M THC. (d) Percent potentiation is plotted as (peak of THC-glycine current / peak glycine current) x 100 for WT GlyR. Data are shown as mean \pm s.e for (n) independent experiments. 0.1 mM Gly/3.2 μ M THC (n = 10) 0.1 mM Gly/32 μ M THC (n = 7) 1 mM Gly/3.2 μ M THC (n = 7). Electrophysiology experiments were performed on independent oocytes, from multiple different surgeries. Unpaired t-test with Welch's correction *** P = 0.0024. N.S = 0.3918. Source data are available as a Source Data file.



Supplementary Figure 2. Cryo-EM analysis of GlyR-THC. (a) Representative micrograph and selected 2D classes showing various particle orientations. (b) Angular distribution of particle projections for the final reconstruction used for model building. The map of the GlyR-THC complex is shown in gray. Nanodisc belts have been removed for clarity. Length of each cylinder corresponds to the number of particles at a specific Euler angle. (c) A side view of the 3D reconstruction color-coded by the local resolution determined using ResMap program algorithm¹ v1.1.5. (d) Gold standard Fourier shell correlation (FSC) curves from RELION 3.1 *(left)*. The dashed line represents an FSC of 0.143. For cross validation of model refinement, FSC curves of the refined model versus summed map (full dataset), refined model versus half map 1 (used during refinement), and refined model versus half map 2 (not used during refinement) *(right)*. (e) Map correlation of the GlyR-THC structure. Validation of various regions within each of the domains of the model (shown as cartoon with stick representation for the residues) and corresponding density map (volume) are shown here.



Supplementary Figure 3. Cryo-EM analysis of GlyR-0.1gly. (a) Select 2D classes. (b) Angular distribution of particle projections for the final reconstruction used for model building. (c) 3D reconstructions color-coded by the local resolution determined using ResMap program (d) Gold standard Fourier shell correlation (FSC) curves from RELION 3.1 *(left)*. The dashed line represents an FSC of 0.143. For cross validation of model refinement, FSC curves of the refined model versus summed map (full dataset), refined model versus half map 1 *(used during refinement), and refined model versus half map 2 (not used during refinement)* (right). (e) Map correlation of GlyR-0.1gly. Validation of various regions within each of the domains of the model (shown as cartoon with stick representation for the residues) and corresponding density map (volume) are shown here.



Supplementary Figure 4. Cryo-EM analysis of GlyR-0.1gly-THC. (a) Select 2D classes. (b) Angular distribution of particle projections for the final reconstruction used for model building. (c) 3D reconstructions color-coded by the local resolution determined using ResMap program. *Inset* shows a zoomed in region of the THC-binding pocket (d) Gold standard Fourier shell correlation (FSC) curves from RELION 3.1 *(left)*. The dashed line represents an FSC of 0.143. For cross validation of model refinement, FSC curves of the refined model versus summed map (full dataset), refined model versus half map 1 *(used during refinement), and refined model versus half map 2 (not used during refinement)* (right). (e) Map correlation of GlyR-0.1gly-THC. Validation of various regions within each of the domains of the model (shown as cartoon with stick representation for the residues) and corresponding density map (volume) are shown here.



1Gly

Supplementary Figure 5. Cryo-EM analysis of GlyR-1gly. (a) Select 2D classes. (b) Angular distribution of particle projections for the final reconstruction used for model building. (c) 3D reconstructions color-coded by the local resolution determined using ResMap program (d) Gold standard Fourier shell correlation (FSC) curves from RELION 3.1 *(left)*. The dashed line represents a n FSC of 0.143. For cross validation of model refinement, FSC curves of the refined model versus summed map (full dataset), refined model versus half map 1 *(used during refinement), and refined model versus half map 2 (not used during refinement)* (right). (e) Map correlation of GlyR-1gly. Validation of various regions within each of the domains of the model (shown as cartoon with stick representation for the residues) and corresponding density map (volume) are shown here.



Supplementary Figure 6. Cryo-EM analysis of GlyR-1gly-THC-State1. (a) Select 2D classes. (b) Angular distribution of particle projections for the final reconstruction used for model building. (c) 3D reconstructions color-coded by the local resolution determined using ResMap program (d) Gold standard Fourier shell correlation (FSC) curves from RELION 3.1 *(left)*. The dashed line represents an FSC of 0.143. For cross validation of model refinement, FSC curves of the refined model versus summed map (full dataset), refined model versus half map 1 *(used during refinement), and refined model versus half map 2 (not used during refinement)* (right). (e) Map correlation of GlyR-1gly-state1. Validation of various regions within each of the domains of the model (shown as cartoon with stick representation for the residues) and corresponding density map (volume) are shown here.



Supplementary Figure 7. Cryo-EM analysis of GlyR-1gly-THC-State 2. (a) Select 2D classes. (b) Angular distribution of particle projections for the final reconstruction used for model building. (c) 3D reconstructions color-coded by the local resolution determined using ResMap program (d) Gold standard Fourier shell correlation (FSC) curves from RELION 3.1 *(left)*. The dashed line represents an FSC of 0.143. For cross validation of model refinement, FSC curves of the refined model versus summed map (full dataset), refined model versus half map 1 *(used during refinement), and refined model versus half map 2 (not used during refinement)* (right). (e) Map correlation of GlyR-1gly-state2. Validation of various regions within each of the domains of the model (shown as cartoon with stick representation for the residues) and corresponding density map (volume) are shown here.

Supplementary Figure 8. Cryo-EM analysis of GlyR-1gly-THC-State 3. (a) Select 2D classes. (b) Angular distribution of particle projections for the final reconstruction used for model building. (c) 3D reconstructions color-coded by the local resolution determined using ResMap program (d) Gold standard Fourier shell correlation (FSC) curves from RELION 3.1 *(left)*. The dashed line represents an FSC of 0.143. For cross validation of model refinement, FSC curves of the refined model versus summed map (full dataset), refined model versus half map 1 *(used during refinement), and refined model versus half map 2 (not used during refinement)* (right). (e) Map correlation of GlyR-1gly-state1. Validation of various regions within each of the domains of the model (shown as cartoon with stick representation for the residues) and corresponding density map (volume) are shown here.

Supplementary Figure 9. Density at the THC binding pocket in the Cryo-EM 3D reconstructions in various states. THC and phospholipid density observed in various GlyR reconstructions. Shown here are RELION 3.1 postprocess maps The maps are displayed at following σ levels: GlyR-Apo (0.010), 0.1Gly (0.016), 1Gly (0.008) GlyR-THC (0.016),

0.1Gly-THC (0.004), and 1Gly-THC-state1 (0.008). Two adjacent units are highlighted for clarity. The region around THC binding pocket is indicated by a box. The nominal resolutions for each map is shown in parenthesis.

Supplementary Figure 10. Assessment of conductance state of GlyR-Apo and GlyR-THC (a) Ion permeation pathway generated with HOLE for GlyR-Apo. For clarity, only two non-adjacent subunits are shown. Colors of the spheres represent the following pore radii: red <1.15 Å, green 1.8–2.3 Å and purple >2.3 Å (b) Mean pore radius and one-standard deviations from three independent 30 ns equilibrium simulations for GlyR-Apo structure along the central pore axis. Major constriction sites are indicated and the dotted line denotes the radius of hydrated chloride ions. The gray trace is the pore radius profile calculated from the cryo-EM structures. (c) Simulation trajectories along the pore (*z*)-axis of water molecules and chloride ion coordinates within 5 Å of the channel axis inside the pore of GlyR-Apo structure, in the presence of a +500 mV transmembrane potential difference (i.e., with the cytoplasmic side having a positive potential). One of five independent 200 ns replicates is shown for each structure. The energetic barriers due to the ring of Leu9' and Pro-2' are at *z* ~0 and -20 Å, respectively. (d) Ion permeation pathway generated for GlyR-THC structure. (e) Mean pore radius profiles and standard deviations averaged across three independent 30 ns equilibrium simulations for GlyR-THC. (f) Simulation trajectories along the pore (*z*)-axis of water molecules and chloride ion coordinates for GlyR-THC.

GLRA3 HUMAN	1 MAHVRHFRTL - VSGFYFWEAALL - L	75
GLRA2_HUMAN	1 MNR - QLVN I LTAL FAF FL <mark>ET NHF</mark> RT AF CKDHDSRSGKQPSQT L <mark>SPS</mark> D <mark>FLDKLMGRT SGYDAR I RPNFKGP PVNV</mark> T CN	76
GLRB_HUMAN	1 MKFLLTTAF LILISLWVEEAYSKEKSSKKGKGKKKQYLCPSQQSAEDLARVPANST <mark>S</mark> NIL NRLLVS <mark>YDPRIRPNFKGIPVDV</mark> VVN	85
GLRA1_HUMAN GLRA1 DANRE	1 MTSFN - I LRLTLWETIVF - F SLAASKEAEAARSAPKPMSPSDFLDKLMGRTSGTDARTRPNFKGPPVNVSCN 1 MF - ALGIYLWETIVF - F SLAASQQA - AARKAASPMPPSE FLDKLMGKVSGYDARTRPNFKGPPVNVTCN	7U 66
C 2007_27002		
01 DA2 100000		
GLRA3_HUMAN GLRA2 HUMAN	76 IFINSFGSTAETIMDYRVNIFLRQKWNDPRLAYSE - YPDDSLDLDPSMLDSIWKPDLFFANERGANFHEVTIDNKLLRIFKNGNVLYSI 1 77 IFINSFGSVTETTMDYRVNIFLRQCWNDSRLAYSE - YPDDSLDLDPSMLDSIWKPDLFFANERGANFHDVTTDNKLLRISKNGKVLYSI 1	63 64
GLRB_HUMAN	86 IFINSFGSIQETTMDYRVNIFLRQKWNDPRLKLPSDFRGSDALTVDPTMYKCLWKPDLFFANEKSANFHDVTQENILLFIFRDGDVLVSM 1	75
GLRA1_HUMAN	71 IFINSFGSIAETTMDYRVNIFLRQQWNDPRLAYNE YPDDSLDLDPSMLDSIWKPDLFFANEKGAHFHEITTDNKLLRISRNGNVLYSI 1	58
GLRA1_DANRE	67 IFINSFGSIAETTMDYRVNIFLRQQWNDPRLAYSE YPDDSLDLDPSMLDSIWKPDLFFANEKGANFHEVTTDNKLLRISKNGNVLYSI 1	54
GLRA3_HUMAN	164 RLTLTLSCPMDLKNFPMDVQTCIMQLESFGYTMNDLIFEWQDEAPVQVAEGLTLPQFLLK-EEKDLRYCTKHYN-TGKFTCIEVRFHLER 2	:51
GLRA2_HUMAN	165 RLTLTLSCPMDLKNFPMDVQTCTMQLESFGYTMNDLIFEWLSDGPVQVAEGLTLPQFILK-EEKELGYCTKHYN-TGKFTCIEVKFHLER 2	.52
GLRB_HUMAN GLRA1 HUMAN	176 RESTIESCPEDETEFPMDIQRCKMQEESFGTTIDDERFTWQSGDPVQEE-RTAEPQFDIRREDTETGNCTRTTRGTGTTTCVEVTFTERR 2 159 Ritelacpmdeknfpmdvotcimolesfgytmndlifewqeogavovadgetepofiek-eekderyctkhyn-tgkftciearfher 2	.64 246
GLRA1_DANRE	155 RITLVLACPMDLKNFPMDVQTCIMQLESFGYTMNDLIFEWDEKGAVQVADGLTLPQFILK-EEKDLRYCTKHYN-TGKFTCIEARFHLER 2	:42
GLRA3 HUMAN	252 QMGYYLIQMYIPSLLIVILSWVSFWINMDAAPARVALGITTVLTMTTQSSGSRASLPKVSYVKAIDIWMAVCLLEVFSALLEYAAVNEVS 3	41
GLRA2_HUMAN	253 QMGYYLIQMYIPSLLIVILSWVSFWINMDAAPARVALGITTVLTMTTQSSGSRASLPKVSYVKAIDIWMAVCLLFVFAALLEYAAVNFVS 3	42
GLRB_HUMAN	265 QVGFYMMGVYAPTLLIVVLSWLSFWINPDASAARVPLGIFSVLSLASECTTLAAELPKVSYVKALDVWLIACLLFGF <mark>A</mark> SLVEYAVVQVML 3	54
GLRA1_HUMAN	247 QMGYYLIQMYIPSLLIVILSWISFWINMDAAPARVGLGITTVLTMTTQSSGSRASLPKVSYVKAIDIWMAVCLLEVESALLEYAAVNEVA 3	36
OLKA I_DANKE		JZ
GLRA3_HUMAN GI RA2 HIIMAN	342 RQHKELLRFRRKRKNKTSRFSFTAYGMGP.CLQA 3	94 83
GLRB_HUMAN	355 NNP <mark>K</mark> RVEAEKA <mark>R</mark> IAKAEQADGKGGNVAKKNTVNGTGTPVHISTLQVGETRCKKVCTSKSDL <mark>R</mark> SNDFSIVGSLPRD <mark>F</mark> ELSN <mark>Y</mark> DCYGKPIEV 4	44
GLRA1_HUMAN	337 RQHKELLRFRRKRRHHKG <mark>RF</mark> NFSAYGMGPACLQA 3	i 84
GLRA1_DANRE	333 RQHKELLRFQRRRRHLGRFSFAAYGMGPACLQA	72
GLRA3_HUMAN	395 KDGMTPKGPNHPVQVMPKSPDEMRKVFIDRAKKIDTISRACFPLAFLIFNIFYWVIYKILRHEDIHQQQD 4	64
GLRA2_HUMAN	384 KDGTAVKAT PANPLPQPPKDGDA I KKKFVDRAKR I DT I SRAAFPLAFL I FN I FYWI TYKI I RHEDVHKK 4	.52
GLRA1 HUMAN	385 KDGISVKGANNSNTTNPPPAPSKSPEEMRKLFIQRAKKIDKISRIGFPMAFLIFNMFYWIIYKIVRREDVHNQ 4	57

GLRA1_HUMAN 385 KDGISVKGANNSNTTNPPPAPSKSPEEMRKLFIQRAKKIDKISRIGFPMAFLIFNMFYWIIYKIVRREDVHNQ--*GLRA1_DANRE* 373 KDGMAIKGNNNNAPTST-NPPEKTVEEMRKLFISRAKRIDTVSRVAFPLVFLIFNIFYWITYKIIRSEDIHKQ--

_

* *

444

Supplementary Figure 11 Multiple sequence alignment of GlyR Sequence of *Danio rerio* GlyR α 1 used in the cryo-EM study and electrophysiological analysis aligned to *Homo sapiens* GlyR α 1, *Homo sapiens* GlyR α 2, *Homo sapiens* GlyR α 3 and *Homo sapiens* GlyR β . Secondary structural elements are indicated for *Homo sapiens* GlyR α 3 (above) and *Danio rerio* GlyR α 1 (below) the sequence. Green line denotes the residues not included in the structural models.

Supplementary Figure 12. Assessment of conductance state of GlyR-1gly and GlyR-1gly-THC

structures (a) Ion permeation pathway along the M2 helices for GlyR-1gly and GlyR-1gly-THC (States 1, 2, and 3). Only two diagonal M2 helices are shown for clarity. Gray box is shown to highlight the constriction at Pro-2' position. (b) Mean pore radius and one-standard deviations from three independent 30 ns equilibrium simulations for GlyR–Apo structure along the central pore axis. (c) Simulation trajectories along the pore (*z*)-axis of water molecules and chloride ion coordinates in the presence of a +500 mV transmembrane potential difference. The energetic barriers due to the ring of Leu9' and Pro-2' are at z ~0 and -20 Å, respectively.

0.1Gly-Docked THC

Supplementary Figure 13. Geometry of the pore during the molecular dynamics simulations.

HOLE transmembrane pore profiles for 0.1Gly-Docked THC states from MS simulation runs. The pore profile represents starting conformation (*initial, left*) and final conformations from three in dependent simulation runs. The gray box is shown to highlight the de-pinching of Pro-2'

Supplementary Figure 14. Putty representations of pairwise deviations for the various GlyR receptor conformations. The selection used for superimposition, and the two conformations used, are noted for each image. Single subunit from each pentamer was used for 3D alignment and only backbone C-alpha RMSD was used for calculation. The RMSD color code and tube thickness scale are presented next to each other.

Supplementary Table 1. Sequence of pCS2-a1 plasmid encoding zebrafish GlyRa1 for expression in *Xenopus laevis* and primers used for mutagenesis.

MFALGIYLWETIVFFSLAASQQAAARKAASPMPPSEFLDKLMGKVSGYDARIRPNFKGP PVNVTCNIFINSFGSIAETTMDYRVNIFLRQQWNDPRLAYSEYPDDSLDLDPSMLDSIWK PDLFFANEKGANFHEVTTDNKLLRISKNGNVLYSIRITLVLACPMDLKNFPMDVQTCIM QLESFGYTMNDLIFEWDEKGAVQVADGLTLPQFILKEEKDLRYCTKHYNTGKFTCIEAR FHLERQMGYYLIQMYIPSLLIVILSWVSFWINMDAAPARVGLGITTVLTMTTQSSGSRAS LPKVSYVKAIDIWMAVCLLFVFSALLEYAAVNFIARQHKELLRFQRRRRHLKEDEAGDG RFSFAAYGMGPACLQAKDGMAIKGNNNNAPTSTNPPEKTVEEMRKLFISRAKRIDTVSR VAFPLVFLIFNIFYWITYKIIRSEDIHKQ

 $S320A_Fwd, CTTCTCTTCGTCTTCGCTGCCCTGCTGGAGTATG$

S320A_Rev, CATACTCCAGCAGGGCAGCGAAGACGAAGAGAA G

W263F_Fwd, ATTGTCATTTTGTCTTTCGTGTCCTTCTGG

W263F_Rev, CCAGAAGGACACGAAAGACAAAATGACAAT

F266A_Rev, GTCCATGTTGATCCAGGCGGACACCCAAGACAA

 $F266A_Fwd, TTGTCTTGGGTGTCCGCCTGGATCAACATGGAC$

W267F_Fwd, TCTTGGGTGTCCTTCTTCATCAACATGGACGC

W267F_Rev, GCGTCCATGTTGATGAAGAAGGACACCCAAGA

P274A_Rev, AACCCCACACGGGCTGCGGCAGCGTCCATGTT

P274A_Fwd, AACATGGACGCTGCCGCAGCCCGTGTGGGGGTT

F418A_rev, GAGGAAGACCAGCGGAGCGGCCACACGCGACAC

F418A_fwd, GTGTCGCGTGTGGGCCGCTCCGCTGGTCTTCCTC

Supplementary Table 2. Codon optimized zebrafish GlyRa1 sequence used for

protein production.

>GlyRalpha1_codon_optimised

ACTAGTATGTTCGCCCTGGGTATCTACCTGTGGGAAACCATCGTGTTCTTCTCCCTGG CTGCTAGCCAGCAGGCTGCTGCTCGCAAGGCCGCTTCCCCTATGCCTCCCAGCGAAT TCCTGGACAAGCTGATGGGCAAGGTGTCCGGCTACGACGCTCGCATCCGTCCCAACT TCAAGGGTCCACCTGTGAACGTCACTTGCAACATCTTCATCAACTCTTTCGGCTCAAT CGCCGAGACTACCATGGACTACAGGGTGAACATCTTCCTGAGACAGCAGTGGAACG ACCCACGTCTGGCTTACTCTGAATACCCTGACGACTCACTGGACCTGGACCCCTCTA TGCTGGACTCAATCTGGAAGCCAGACCTGTTCTTCGCCAACGAGAAGGGCGCTAACT TCCACGAAGTGACCACTGACAACAAGCTGCTGAGGATCTCCAAGAACGGAAACGTG CTGTACAGCATCAGAATCACCCTGGTCCTGGCCTGCCCTATGGACCTGAAGAACTTC CCCATGGACGTCCAGACCTGCATCATGCAGCTGGAGTCCTTCGGTTACACTATGAAC GACCTGATCTTCGAGTGGGACGAAAAGGGTGCTGTGCAGGTGGCTGACGGACTGAC CCTGCCTCAGTTCATCCTGAAGGAGGAAAAGGACCTGCGCTACTGCACTAAGCACT ACAACACCGGAAAGTTCACTTGCATCGAGGCTCGCTTCCACCTGGAACGTCAGATG GGTTACTACCTGATCCAGATGTACATCCCCAGCCTGCTGATCGTGATCCTGTCCTGG ACTGTCCTGACTATGACCACTCAGTCCAGCGGCTCTAGAGCTTCACTGCCCAAGGTG TCCTACGTCAAGGCCATCGACATCTGGATGGCTGTGTGCCTGCTGTTCGTCTTCAGC GCCCTGCTGGAGTACGCCGCTGTGAACTTCATCGCTCGCCAGCACAAGGAACTGCTG CGTTTCCAGCGCCGTAGGAGACACCTGAAGGAGGACGAAGCTGGAGACGGAAGGTT CTCTTTCGCCGCTTACGGCATGGGACCAGCCTGCCTGCAGGCTAAGGACGGAATGGC CATCAAGGGTAACAACAACAACGCTCCTACCTCAACTAACCCTCCTGAGAAGACCG TGGAGGAAATGCGCAAGCTGTTCATCTCTAGGGCCAAGAGAATCGACACTGTGTCA CGTGTCGCTTTCCCTCGGTCTTCCTGATCTTCAACATCTTCTACTGGATCACCTACA AGATCATCCGCTCCGAAGACATCCACAAGCAGCTGGTTCCGCGTGGTAGTCATCACC ATCACCATCACCATCACTAAGGTACC

Sample	GlyR-THC	GlyR-0.1gly-THC	GlyR-0.1gly
PDBid	7M6M	7M6O	7M6N
EMDB id	23700	23702	23701
Data Collection and processing			
Microscope and location	FEI Titan Krios, Frederick National Laboratory for Cancer Research	SLAC	FEI Titan Krios, Case Western Reserve University
Magnification	81000	130000	81000
Voltage	300	300	300
Data collection mode	super-resolution	super-resolution	super-resolution
Camera	К3	K3	K3
Physical pixel size	1.08 Å/pixel	0.68 Å/pixel	1.1 Å/pixel
Defocus range (uM)	-1.0 to -2.0	-1.0 to -2.0	-0.8 to -1.8
Number of movie	5760	5803	7844
Dose per frame	1.45 e-/Å2	1.25	0.85
Number of frames/movie	40	50	70
Initial particle number	124240	190380	147734
Final particle number	22238	29664	89791
Symmetry	C5	C5	C5
Resolution (unmasked, Å)	3.53 Å	3.4 Å	3.11 Å
Resolution (masked, Å)	3.09 Å	2.84 Å	2.61 Å
Map resolution range *	2-8	2-8	2-8
Map sharpening B-factor (Å ²)	-30	-30	-30
Refinement			
Initial model used (PDB code)	6UBS	6UBS	6UBS
Composition			
Protein residues	1720	1785	1805
Non Hydrogen atoms	14190	14670	14700
Glycan (NAG) (molecule)	10	5	5
Glycine (molecule)	0	5	5
TCI	5	5	0
Bonds (RMSD)			
Length (Å) ($\# > 4\sigma$)	0.008(0)	0.009(0)	0.009(0)
Angles (°) ($\# > 4\sigma$)	1.327(5)	1.374(30)	1.276(0)
Ramachandran plot (%)			
Outliers	0	0	0
Allowed	3.71	3.1	1.68
Favored	96.29	96.9	98.32
Rotamer outliers (%)	0	0	0
Molprobity score	1.41	1.43	1.26
Molprobity clashscore	3.69	5.24	4.89
* Local resolution range	2-8Å	2-8Å	2-8Å

Supplementary Table 3 Cryo-EM data collection, refinement and validation statistics.

Sample GlyR-1gly-THC			GlyR-1gly	
PDBid	7M6Q	7M6R	7M6S	7M6P
EMDB id	23704	23705	23706	23703
Data Collection and processing	State1	State2	State3	
Microscope and location	FEI Titan Krios, Case Western Reserve University			FEI Titan Krios, Case Western Reserve University
Magnification	Magnification 81000		81000	
Voltage	300			300
Data collection mode	super-resolution			super-resolution
Camera	K3			К3
Physical pixel size	1.1 Å/pixel			1.1 Å/pixel
Defocus range (uM)	-1.0 to -2.0			-1.0 to -2.0
Number of movie		4336		5822
Dose per frame	1.2			0.85
Number of frames/movie	40			70
Initial particle number	323908			189243
Final particle number	77813	44653	18156	29483
Symmetry	C5	C5	C5	C5
Resolution (unmasked, Å)	3.5 Å	4.2 A	4.33 Å	3.82 Å
Resolution (masked, Å)	2.91 Å	3.57 Å	3.61 A	3.28 Å
Map resolution range *	2-8	2-8	2-8	2-8
Map sharpening B-factor (Å ²)	-30	-30	-30	-30
Refinement				
Initial model used (PDB code)	6UBS	6UBS	6UBS	6UBS
Composition				
Protein residues	1795	1755	1785	1795
Non Hydrogen atoms	14725	14300	14600	14650
Glycan (NAG) (molecule)	5	0	0	5
Glycine (molecule)	5	0	0	5
TCI	5	0	0	0
Bonds (RMSD)				
Length (Å) ($\# > 4\sigma$)	0.008(0)	0.008(0)	0.009(0)	0.008(0)
Angles (°) ($\# > 4\sigma$)	1.152(10)	1.201(0)	1.403(27)	1.266(5)
Ramachandran plot (%)				
Outliers	0	0	0	0
Allowed	3.1	3.47	3.1	3.1
Favored	96.9	96.53	96.9	96.9
Rotamer outliers (%)	0	1	2	0
Molprobity score	1.5	1.45	1.53	1.46
Molprobity clashscore	5.7	4.44	6.25	5.18
* Local resolution range	2-8Å	2-8Å	2-8Å	2-8Å

Supplementary Table 4 Cryo-EM data collection, refinement and validation statistics.

Supplementary References

1. Swint-Kruse, L. & Brown, C.S. Resmap: automated representation of macromolecular interfaces as two-dimensional networks. *Bioinformatics* **21**, 3327-8 (2005).